Premium
Intravenous self‐administration of benzydamine, a non‐steroidal anti‐inflammatory drug with a central cannabinoidergic mechanism of action
Author(s) -
Avvisati Riccardo,
Meringolo Maria,
Stendardo Emiliana,
Malavasi Elisa,
Marinelli Silvia,
Badiani Aldo
Publication year - 2018
Publication title -
addiction biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 78
eISSN - 1369-1600
pISSN - 1355-6215
DOI - 10.1111/adb.12516
Subject(s) - nucleus accumbens , pharmacology , medicine , neuroscience , addiction , mechanism of action , electrophysiology , neurotransmission , chemistry , receptor , psychology , in vitro , biochemistry
Benzydamine (BZY) is a non‐steroidal anti‐inflammatory drug used for the topical treatment of inflammations of the oral and vaginal mucosae. Virtually nothing is known about the central pharmacological actions of BZY. Yet there are reports of voluntary systemic overdosage of BZY in drug addicts, resulting in a euphoric, hallucinatory state. In the present study, we investigated the reinforcing properties of BZY in a rat self‐administration paradigm. We found that BZY has a powerful reinforcing effect and that this effect is greatly facilitated in animals that already had substance experience, having previously self‐administered heroin and cocaine, indicating cross sensitization between BZY and other common drugs of abuse. We then assessed the effect of BZY on prelimbic cortex‐to‐nucleus accumbens glutamatergic transmission, using field recordings in rat parasagittal brain slices. BZY dose‐dependently reduced both field excitatory post synaptic potential amplitude and paired pulse ratio, suggesting a presynaptic mechanism of action. Similarly to the in vivo paradigm, also the electrophysiological effects of BZY were potentiated in slices from animals that had undergone cocaine and heroin self‐administration. Furthermore, BZY‐induced Long Term Depression (LTD)‐like responses in the prelimbic cortex‐to‐nucleus accumbens circuitry were significantly reduced in the presence of the CB1 receptor antagonist AM251. These findings provide firm evidence of the abuse liability of BZY and suggest a possible cannabinoidergic mechanism of action. Further research is needed in order to give insights into the molecular mechanism underlying BZY psychoactive and reinforcing effects, to better understand its abuse potential.